Objectives-Brachial artery flow-mediated dilatation on sonography is used to evaluate endothelial dysfunction, which is a key event in the development of atherosclerosis and predates structural atherosclerotic lesions by many years. Atherosclerosis has been implicated in the pathophysiologic mechanisms of ischemic stroke. The aim of this study was to determine the association between brachial flow-mediated dilatation, the presence of cardiovascular risk factors, and acute stroke.
S
troke is defined by the World Health Organization as rapidly developing signs of focal or global disturbance of cerebral or intracranial neuronal function, with symptoms lasting more than 24 hours or leading to death of the patient with no apparent cause other than that of a vascular origin. 1 Stroke is a global disease, and it affects all age groups, including adults, young children, infants, and fetuses. 1 It is also a major cause of death worldwide, second to ischemic heart disease, and a leading cause of disability in adults.
The early presence of atherosclerosis predates many stroke cases, and vascular endothelial dysfunction plays a pivotal role in the development, progression, and clinical manifestations of atherosclerosis. 3 Endothelial dysfunction is a pathologic state of the endothelium and can be broadly defined as an imbalance between vasodilating and vasoconstrictive substances produced by (or acting on) the endothelium. 4 Several methods have been used to measure endothelial function in humans. 5 These include measurement of morphologic and mechanical characteristics of the vascular wall (eg, intima-media thickness, compliance, distensibility, and remodeling indices), determination of soluble endothelial markers (eg, von Willebrand factor, plasminogen activator, inhibitor complex, thrombomodulin adhesion molecules, and N-oxides), and measurement of the endotheliumdependent regulation of vascular tone at focal sites in the circulation in response to physiologic shear stress (flow-mediated vasodilatation) or pharmacologic stimuli (acetylcholine). 6 Endothelial dysfunction is widely assessed with high-resolution sonography by measuring brachial artery flow-mediated dilatation, which is simple, noninvasive, inexpensive, readily available, and reproducible. This study evaluated flow-mediated dilatation in the brachial arteries by sonography in stroke patients, comparing findings in nonstroke participants with and without cardiovascular risk factors.
Materials and Methods

Study Population
We conducted a cross-sectional prospective case-control study consisting of 3 groups: 50 consecutively recruited first-ever stroke patients, 50 nonstroke participants with cardiovascular risk factors similar to those of the stroke patients, and 50 healthy control individuals without cardiovascular risk factors. The groups were matched for age and sex, and the risk factor and stroke groups were matched for traditional cardiovascular risk factors in addition to stroke. These risk factors included hypertension, diabetes mellitus, obesity, smoking, alcohol consumption, dyslipidemia, and hypercreatinemia. None of the female participants in the risk factor group were taking oral contraceptive pills, according to a review of their medical records. The exclusion of stroke in the risk factor and control groups was based on clinical signs, symptoms, and clinical examinations.
Fifty patients aged 18 to 90 years with neuroimagingconfirmed stroke diagnosed within 10 days of the event were recruited prospectively. The study was conducted in the neurology unit of the Obafemi Awolowo University Teaching Hospitals Complex between December 2013 and November 2014. The risk factor group had cardiovascular risk factors similar to those in the stroke group. The controls had no cardiovascular risk factor or disease, and their physical examination and laboratory results were normal. Written informed consent was obtained from all of the study participants. The study protocol was approved by the Institutional Ethics Committee of the Obafemi Awolowo University Teaching Hospitals Complex.
Biochemical Evaluation
The participants had their blood drawn for fasting blood sugar, lipid profile, and serum creatinine testing, and their samples were analyzed in the chemical pathology laboratory of the hospital.
Sonographic Evaluation of Brachial Artery Flow-Mediated Dilatation
Brachial artery flow-mediated dilatation evaluations using an electrocardiographically gated DC-7 realtime ultrasound scanner (Mindray, Shenzhen, China) equipped with a variable high-frequency linear array transducer with a frequency range of 7.5 to 12 MHz were conducted on all participants. To avoid diurnal variation in flow-mediated dilatation, 7 all participants had their dilatation measured between 8 AM and 10 AM after an overnight fast of at least 8 hours. All participants were asked to abstain from caffeine and tobacco for at least 8 hours before the examination and night work before the examination. For the stroke and risk factor participants taking vasodilators, all medications were withheld on the morning of the examination until after the examination. The examination room temperature was maintained at 268C to 288C.
All participants were allowed 10 to 15 minutes of rest in the quiet examination room before the brachial artery Doppler examination began. Since a validated brachial artery (right or left) was not stated by the International Brachial Artery Task Force, 8 the right arm, as used by previous authors, was chosen for this study. 9, 10 With the participants lying supine, appropriate exposure and 158 of abduction of the right arm were obtained. Coupling gel was applied to the arm 3 to 5 cm above the elbow. The examination of the right brachial artery of each participant was performed according to the protocol described by Corretti et al. 11 Machine operating parameters were kept constant during each study.
The brachial artery was scanned in a longitudinal section 5 to 10 cm above the elbow wherever the clearest sonogram was obtained. Images were acquired perpendicular to the ultrasonic beam and along the long axis of the brachial artery from the near-far wall blood interface. Straight arterial wall segments were obtained with both walls clearly visualized for optimal diameter measurements. When a reasonable image was obtained, the surface of the skin was marked, and the arm was kept in the same position throughout the study. The luminal diameter was measured as the distance between the anterior intima-lumen interface to the posterior intima-lumen interface and was tagged diameter 1. A blood pressure cuff was then applied to the forearm below the elbow and inflated to 50 mm Hg above the systolic blood pressure for 5 minutes to elicit an endothelium-mediated response before being released. Forearm occlusion was used because it caused less patient discomfort and made it easier to visualize the brachial artery on sonography during cuff inflation and deflation. 9 The cuff was deflated after 5 minutes of cuff occlusion of the forearm. The same brachial artery segment underneath the marked skin area was interrogated continuously for 30 seconds before and 90 seconds after cuff deflation. The diameter tagged diameter 2 was measured between 60 and 90 seconds after release of the cuff. Determination of this timing was based on the time course change in the brachial artery diameter after cuff release, which was observed in 5 male participants during a pilot study. The preliminary study showed that maximum dilatation was observed 60 to 90 seconds after cuff release. The diameter of the brachial artery after cuff release (diameter 2) was taken as the maximum diameter obtained between 60 and 90 seconds after cuff release. All measurements were made during systole, since the artery expands to accommodate the increase in pressure and volume generated by the left ventricular contraction at this phase of the cardiac cycle. Also, the magnitude of systolic expansion is affected by vessel compliance; therefore, effects of cardiovascular risk factors and disease will be maximally seen during systole. 11 The average of 3 measurements was used for flowmediated dilatation calculation. Flow-mediated dilatation was calculated as the percentage of change in the diameter after reactive hyperemia relative to the baseline by the following formula 12 : % flow-mediated dilatation 5 (diameter 2 -diameter 1)/diameter 1 3 100%.
Statistical Analysis
Statistical analysis was performed with SPSS version 20.0 software (IBM Corporation, Armonk, NY). All data were expressed as mean 6 standard deviation. Analysis of variance for multiple comparisons was used between each group. P < .05 was considered statistically significant. Data are presented as mean 6 SD (range) and mean 6 SD where applicable.
Omisore
Results
Sociodemographic and Clinical Characteristics of the Study Participants
There were no significant differences in age and sex between the groups (Table 1) ; however, they differed significantly in body mass index, systolic blood pressure, diastolic blood pressure, mean arterial pressure, total cholesterol, total triglycerides, low-density lipoprotein, high-density lipoprotein, serum creatinine, and fasting blood sugar (Table 1 ; P < .05).
The risk factor and stroke groups were comparable in terms cardiovascular risk factors, including age, sex, hypertension, diabetes mellitus, dyslipidemia, alcohol consumption, smoking, obesity, and hypercreatinemia (Table 2) . They also had comparable burdens of cardiovascular risk factors: ie, mean number of risk factors (1.6 6 0.9 versus 1.7 6 0.8; P 5 .435).
Of the 50 stroke patients, 13 (26%) had intracerebral hemorrhage whereas the remaining 37 (74%) had ischemic stroke. In the ischemic group, most patients had nonlacunar stroke, followed by lacunar stroke and cardioembolic stroke.
Comparison of Mean Flow-Mediated Dilatation
Between the Stroke, Risk Factor, and Control Groups One-way analysis of variance revealed significant differences in mean flow-mediated dilatation across the groups (P < .001). Scheff e post hoc analysis further revealed that the groups differed significantly from each another in terms of mean flow-mediated dilatation (Table 3) .
Comparison of Mean Brachial Artery Flow-Mediated Dilatation in Different Stroke Types and Subtypes
Brachial flow-mediated dilatation was significantly lower (P < .001) in patients with ischemic stroke (3.79% 6 0.92%) compared with intracerebral hemorrhage (6.02% 6 1.62%; Figure 1 ).
Subgroup analysis revealed that flow-mediated dilatation was lowest among patients with nonlacunar stroke and highest in patients with cardioembolic stroke. However, this differences did not reach statistical significance (Table 4) .
Discussion
In this study, mean brachial artery flow-mediated dilatation was significantly lower in individuals with acute stroke compared with those without stroke who had risk Data are presented as mean 6 SD. Scheff e post hoc analysis: P <.001, control versus risk factors; P <.001, control versus stroke; P 5.001, stroke versus risk factors. factors (P < .05) and healthy control participants (P < .05). Individuals without stroke but with traditional cardiovascular risk factors were comparable with the acute stroke patients, as they also had lower dilatation compared with the healthy individuals without cardiovascular risk factors (P < .05). The lower dilatation value found in the stroke group could not be attributed to cardiovascular risk factors alone because both the risk factor and stroke cases had comparable risk factor prevalence rates except for hypercholesterolemia (6 stroke cases versus 20 risk factor cases) and obesity (29 stroke cases versus 15 risk factor cases; P < .05). Stenborg et al 13 used a similar case-control design to compare endothelial function between healthy controls matched for age and sex, hypertension-matched controls, and stroke cases with mean age of about 70 years. In contrast to this study, they measured endothelium-dependent vasodilatation in the forearm using venous plethysmography, whereas endothelium-dependent vasodilatation was measured in this study by using brachial artery flow-mediated dilatation. They found significantly lower vasodilatation in the stroke group compared with healthy controls (P < .001) but no significant difference in vasodilatation between the stroke and hypertensive control groups (P 5 .27). The fact that we included 6 other traditional cardiovascular risk factors in addition to hypertension can account for the difference between the stroke and risk factor groups in our study, which could suggest synergism between these risk factors for impairment of endothelial dysfunction to occur. Similar to the findings of this study, the hypertensive controls had lower vasodilatation compared with the healthy controls (P < .001). The lower flowmediated dilatation observed in the acute stroke patients in our study is proposed to have been due to circulatory proinflammatory molecules, oxidative stress found in the acute phase of stroke, or both.
14 This study therefore shows that flow-mediated dilatation not only is a marker of cardiovascular risk but may also be a probable reactant in the acute phase of stroke.
Estrogen-containing oral contraceptive pills have been found to protect women from athrogenesis 15 and thus improve the endothelial function of arteries. No female participants the risk factor and stroke groups in this study were taking oral contraceptive pills. This finding is not surprising because the mean age of our participants was in the sixth decade.
The plasma homocysteine level has a procoagulative effect and can induce endothelial damage by increasing the activity of plasma prothrombin and coagulation factors XII and V and decreasing the activity of protein C and thrombomodulin expression on the endothelial membrane. 16 Homocysteine has also been documented as an atherogenic risk factor for stroke by increasing matrix metalloproteinase activity, which is an enzyme present in atherosclerotic plaque and can lead to instability and rupture. 16 However, an interstroke study by O'Donnell et al 17 showed that traditional cardiovascular risk factors still accounted for most of the populationattributable risk of stroke, which was the focus in this study. Further work on endothelial dysfunction by us would explore homocysteine and other novel cardiovascular risk factors, especially in long term follow-up of the risk factor group to the possible end point of stroke. Atherosclerosis is a complex multifactorial arterial disease involving interactions of multiple genetic and environmental factors. 18 Before the development of atherosclerotic plaque, endothelial vasodilator function is impaired early in the process of atherogenesis. 18 Genetic factors have been implicated in atherogenesis. Genetic variations in coagulation factors and fibrinogen are responsible for increased atherogenicity. 18 Notable among these factors are deficiencies in protein S, protein C, and antithrombin, factor V Leiden, the prothrombin G20210A mutation, plasminogen activator inhibitor 14G/5G polymorphism, and MTHFR (methylene tetrahydrofolate reductase). 18 Noninclusion of these genetic cardiovascular risk factors in our study limits the findings from this study.
After establishing in this study that there was lower flow-mediated dilatation in stroke patients compared with the risk factor and control groups, a comparison of the dilatation between the stroke types and subtypes revealed that impaired dilatation was particularly related to cerebral infarction rather than hemorrhagic stroke (P < .001). Researchers have singled out the ischemic stroke type in studies on endothelial dysfunction. However, hemorrhagic stroke cases were included in this study, in similarity to the study by Stenborg et al 13 on endothelium-dependent vasodilatation in stroke patients, as assessed by venous plethysmography. However, they did not compare vasodilatation between ischemic and hemorrhagic groups. Furthermore, endothelial dysfunction measured by brachial artery flowmediated dilatation in this study was not statistically different between the ischemic stroke subtypes (nonlacunar, lacunar, and cardioembolic), according to Trial of ORG 10172 in Acute Stroke Treatment classification. Some authors, however, demonstrated impaired flowmediated dilatation between different subtypes of ischemic stroke. Chen et al 19 studied stroke patients whom they also classified by using the Trial of ORG 10172 in Acute Stroke Treatment criteria, as in this study. They found significantly lower flow-mediated dilatation in patients with lacunar stroke compared with healthy controls, patients with large-artery stroke, and those with cardioembolic stroke. The lacunar patients had flowmediated dilatation of 4.3% 6 6.1%, whereas the controls had dilatation of 8.8% 6 6.0%. The large-artery stroke and cardioembolic stroke groups had dilatation rates of 5.7% 6 5.4% and 5.6% 6 5.0%, respectively.
Some authors even singled out some ischemic subtypes and compared them with controls, whereas others compared only some and not all of the ischemic stroke subtypes in their studies of endothelial dysfunction. For example, Pretnar-Oblak et al 20 studied lacunar stroke cases and risk factor controls. Flow-mediated dilatation was significantly impaired among the lacunar group (0.4% 6 5.0%) compared with the risk factor group (3.8% 6 4.8%) in that study.
A limitation of the study was that we did not evaluate novel and genetic factors, which are consequential determinants of atherosclerotic cardiovascular disease risk. These will be considered for evaluation in our subsequent studies on endothelial dysfunction. Another limitation was that only patients who survived stroke were enrolled. It cannot be excluded that the degree of endothelial dysfunction may worsen with the severity of stroke; thus, degree of impairment by endothelial dysfunction in stroke patients may have been underestimated in this study. A referral bias may also have been introduced by the university hospital setting but was probably reduced by testing all consecutive patients with cardiovascular risk factors and stroke.
In conclusion, decreased vascular endothelial function was seen in the presence of cardiovascular risk factors and stroke. Flow-mediated dilatation was significantly lower in cerebral infarction than intracerebral hemorrhage. There were no differences in brachial flow-mediated dilatation between ischemic stroke subtypes according to the Trial of ORG 10172 in Acute Stroke Treatment classification. Brachial artery flowmediated dilatation is therefore recommended as a screening tool for assessing cardiovascular risk in populations at risk and for monitoring patients with cardiovascular risk factors such as hypertension for evaluation of progression to end-point cardiovascular diseases such as stroke.
